Andrew Armanino - Oct 28, 2021 Form 3 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Director
Signature
/s/ Mark Heinen, Attorney-in-Fact for Andrew J. Armanino
Stock symbol
BTTX
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
3
Date filed
11/1/2021, 08:35 PM
Previous filing
Aug 20, 2021
Next filing
Nov 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BTTX Common Stock 13.3K Oct 28, 2021 Direct F1, F2
holding BTTX Common Stock 48.3K Oct 28, 2021 By Armanino Trust F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination").
F2 At the effective time of the Business Combination, each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475, with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc.
F3 These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust.

Remarks:

Exhibit 24 - Power of Attorney